IP Library › Granted Patent US 10,660,915
Granted Patent B2
US 10,660,915 · App. 15/526,294 · Granted May 26, 2020

Method for induction of T cells from pluripotent stem cells

Inventors: Shin Kaneko (Kyoto, JP); Atsutaka Minagawa (Kyoto, JP); Yutaka Yasui (Kyoto, JP)
Assignee: Kyoto University
A61K35/14A61K35/17C12N5/0636C12N5/0696C12N5/10C12N5/163C12N5/00C12N2501/125C12N2506/11C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,660,915
App. No.
15/526,294
Granted
May 26, 2020
Kind
B2
Abstract

The present invention provides a method for efficiently inducing CD8-positive T cells by adding vitamin C to the medium in the steps of induction of the CD8-positive T cells from pluripotent stem cells. The present invention also provides a method for efficiently inducing CD8-positive T cells by performing culture in a medium supplemented with an adrenocortical hormone agent in the step of induction of the CD8-positive T cells from CD4/CD8 double-positive T cells.

Claims (17)

1. A method for inducing CD8-positive T cells, comprising the step of culturing CD4/CD8 double-positive T cells in a medium supplemented with an adrenocortical hormone agent and IL-7, wherein the adrenocortical hormone agent is glucocorticoid or a derivative thereof.

2. The method according to claim 1 , wherein prior to said step of culturing the CD4/CD8 double-positive T cells in a medium supplemented with said adrenocortical hormone agent and interleukin (IL)-7, the method comprises the steps of:

(1) culturing pluripotent stem cells in a medium supplemented with vitamin C and vascular endothelial growth factor (VEGF) to induce hematopoietic progenitor cells; and

(2) culturing cells obtained in said Step (1) in a medium supplemented with vitamin C, FLT-3L and IL-7 to induce the CD4/CD8 double-positive T cells.

3. The method according to claim 2 , wherein said vitamin C is vitamin C phosphate.

4. The method according to claim 2 , wherein the vitamin C is supplied to the medium every day.

5. The method according to claim 2 , wherein, in said Step (1), the pluripotent stem cells are cultured on C3H10T1/2 cells.

6. The method according to claim 2 , wherein said Step (1) is carried out under low oxygen conditions with an oxygen concentration of not more than 5%.

7. The method according to claim 2 , wherein, in said Step (1), the medium further comprises Stem cell factor (SCF), and Flt3 Ligand (FLT-3L).

8. The method according to claim 2 , wherein, in said Step (2), the cells obtained in Step (1) are cultured on OP9-DL1 cells.

9. The method according to claim 1 , wherein said adrenocortical hormone agent is dexamethasone.

10. The method according to claim 1 , wherein said medium further comprises an anti-CD3 antibody, vitamin C, and IL-2.

11. The method according to claim 10 , wherein said vitamin C is vitamin C phosphate.

12. The method according to claim 2 , wherein, in said Step (1), the pluripotent stem cells are cultured on feeder cells.

13. The method according to claim 2 , wherein, in said Step (2), the cells obtained in Step (1) are cultured on feeder cells.

14. The method according to claim 1 , wherein said medium further contains a T cell stimulant.

15. The method according to claim 1 , wherein the adrenocortical hormone agent is selected from the group consisting of cortisone acetate, hydrocortisone, fludrocortisone acetate, prednisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclometasone dipropionate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: KANEKO, SHIN; MINAGAWA, ATSUTAKA; YASUI, YUTAKA
To: KYOTO UNIVERSITY
Reel/Frame 043120/0765 →
Priority Claims (1)
JP 2014-230355 · Nov 13, 2014 · national
Continuity (1)
Related Publication 20170326175A1 · Nov 16, 2017
Cited By (1)
US 12,391,739